Washington Research Foundation Awards $5.2M to Launch Collaborative Clinical Trials Program for Rare Cancer Therapeutics
核心洞察
The Washington Research Foundation (搜索) has awarded $5.2 million to establish a collaborative clinical trials program between Fred Hutch Cancer Center (搜索) and Seattle Children's Research Institute focusing on first-in-human studies of novel therapeutics for rare cancers (搜索).
The program will prioritize two engineered T-cell therapies: a TCR T-cell therapy for high-risk acute myeloid leukemia (搜索) in adults and a CAR T-cell therapy for AML (搜索) in children, selected from over a dozen evaluated technologies.
Four million dollars will directly support four Phase 1 clinical trials (two at each institution), while $1.2 million will fund strategic planning and infrastructure development to create a sustainable framework for translating innovative therapies.
The Washington Research Foundation (搜索) has awarded $5.2 million to establish a groundbreaking collaborative clinical trials program between Fred Hutch Cancer Center (搜索) and Seattle Children's Research Institute, marking a significant investment in advancing novel therapeutics for rare cancers (搜索) and other diseases affecting both adults and children.
The program, titled "Bridging the Clinical Gap: Adding Value to the 'Discovered Here in Washington' Therapeutic Ecosystem," will focus specifically on first-in-human clinical studies of brand-new therapeutics developed by both institutions. Dr. Folashade "Shade" Otegbeye, facility director of the Therapeutic Products Program at Fred Hutch, and Dr. Mignon Loh, director of the Ben Towne Center for Childhood Cancer and Blood Disorders Research at Seattle Children's, will co-lead this initiative.
Strategic Focus on Engineered T-Cell Therapies
Building on a previous $200,000 WRF grant that enabled evaluation of more than a dozen technologies, the research teams have identified two priority therapeutic approaches for development. The program will advance an engineered tumor cell receptor (搜索) (TCR (搜索)) T-cell therapy targeting high-risk acute myeloid leukemia (搜索) in adult patients, alongside a CAR T-cell therapy designed for AML (搜索) treatment in children.
"There is exceptional expertise in cell, gene, and protein therapeutics discovery and translational research across Fred Hutch and Seattle Children's," Otegbeye explained. "Each institution has independently invested in infrastructure supporting key stages of the bench-to-bedside continuum. By strategically leveraging our complementary infrastructure and expertise, we can more sustainably advance first-in-human studies, particularly as traditional research funding streams become increasingly constrained."
Funding Allocation and Infrastructure Development
The three-year grant will be strategically divided to maximize clinical impact. Four million dollars will provide direct support for four Phase 1 clinical trials, with two trials conducted at each institution and matching commitments from both Fred Hutch and Seattle Children's Research Institute.
The remaining $1.2 million will fund strategic planning and infrastructure development essential for launching these clinical trials. This investment will also establish "a sustainable framework for translating other innovative therapies from both institutions," according to Otegbeye, who holds the Fred Hutch Fleischauer Family Endowed Chair in Cell and Gene Therapy Translation.
Addressing Clinical Translation Challenges
The collaborative program addresses a critical gap in therapeutic development. While both Fred Hutch and Seattle Children's routinely conduct clinical trials, the "one-off" nature of clinical trial funding creates challenges for institutions attempting to strategically monitor their pipelines and conduct advance planning for bringing promising products to patients.
First-in-human studies at research institutions often represent the only pathway for patients to access leading-edge therapies while providing crucial evidence of a drug's safety and efficacy that could enable development at scale. The research teams are also evaluating methods to create time- and resource-efficient approaches for translating protein therapeutic research into first-in-human trials.
Broader Impact on Washington's Life Sciences Ecosystem
The grant represents part of WRF's BioInnovation Grants program, designed to increase support for significant, emerging opportunities to advance Washington state's life sciences ecosystem and improve patient outcomes. Since its founding in 1981, WRF has provided over $184 million in grants to the state's research institutions to assist with technology commercialization.
"WRF has long recognized the value of our most inventive research institutions translating their research expertise into actual clinical impact," said Dr. Meher Antia, WRF's director of grant programs. "By partnering with Fred Hutch and Seattle Children's and leveraging the strong financial and operational support from these institutions, our funding can help to strengthen the pipeline of early-stage research that actually reaches patients for their benefit and also demonstrates potential for future commercialization."
Otegbeye emphasized the broader significance of advancing "discovered here in Washington" technologies, stating: "Recognizing our shared responsibility to ensure that our collective science tangibly improves lives across Washington, we have an opportunity — and an obligation — to collaborate intentionally."